BioCentury | Jan 8, 2021
Finance

Jan. 8 Quick Takes: Venture rounds for Abbisko, DiCE, Aulos, LifeMine, Mana, Theolytics and more

...completion of its merger with special purpose acquisition company GX Acquisition Corp. (Nasdaq: GXGX). A syndicate including Starr...
BioCentury | Mar 5, 2020
Product Development

March 4 Quick Takes: Arcturus-Duke-NUS collaborate on COVID-19 vaccine; plus Gilead, Roche, Editas-Allergan, Alnylam, FDA

...Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) and Duke-NUS Medical School are collaborating to use the company’s STARR...
...the university’s rapid vaccine screening platform to develop a vaccine against SARS-CoV-2 for Singapore. Arcturus’ STARR...
BioCentury | Jan 29, 2020
Company News

Decibel narrows discovery focus to inner ear regeneration, taps Reid as CEO

...remain a strategic adviser to Decibel (see "Branching Out" ). Holtzman succeeded Third Rock's Kevin Starr...
BioCentury | Aug 7, 2019
Financial News

Glycomine looks toward clinic with Novo-led $33M round

...joined Glycomine's board, as did BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and Raptor Pharmaceutical Corp. co-founder Chris Starr...
BioCentury | Jun 2, 2017
Product Development

Ears wide open

...important because they start to change how ENTs work and how they prescribe treatments." Kevin Starr...
...because they start to change how ENTs work and how they prescribe treatments,” said Kevin Starr...
...or pathways it is working on. Decibel is not developing therapies that deliver NFT3, but Starr...
BioCentury | Jul 14, 2016
Company News

Decibel hires Holtzman as CEO

...Millennium Pharmaceuticals Inc. , which Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) acquired. Third Rock Ventures' Kevin Starr...
...remain its chairman. Third Rock led Decibel's $52 million series A round in October 2015. Starr...
BioCentury | Jan 11, 2016
Emerging Company Profile

Synaptic sound

...or other injuries mean your hair cells are gone," said Chairman and interim CEO Kevin Starr...
...we can generate a therapy that makes the synapse healthier, we can help improve hearing." Starr...
...children often go on to get cochlear implants and grow up to be deaf," said Starr...
BioCentury | Oct 19, 2015
Finance

Sound check

...and hearing disorders were not going to be a black box," said the firm's Kevin Starr...
...product in the clinic in three years. The series A will last that long, said Starr...
...play Otonomy Inc. (NASDAQ:OTIC). Compared with those companies, which house one or two key assets, Starr...
BioCentury | Oct 16, 2015
Financial News

Decibel raises $52M series A

...loss. Decibel is not disclosing the precise mechanisms of its preclinical programs. Third Rock's Kevin Starr...
BioCentury | Jun 24, 2015
Company News

Agios makes boardroom changes

...York, N.Y.). Ho was a partner at Goldman Sachs Group. Third Rock Ventures partner Kevin Starr...
Items per page:
1 - 10 of 54
BioCentury | Jan 8, 2021
Finance

Jan. 8 Quick Takes: Venture rounds for Abbisko, DiCE, Aulos, LifeMine, Mana, Theolytics and more

...completion of its merger with special purpose acquisition company GX Acquisition Corp. (Nasdaq: GXGX). A syndicate including Starr...
BioCentury | Mar 5, 2020
Product Development

March 4 Quick Takes: Arcturus-Duke-NUS collaborate on COVID-19 vaccine; plus Gilead, Roche, Editas-Allergan, Alnylam, FDA

...Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) and Duke-NUS Medical School are collaborating to use the company’s STARR...
...the university’s rapid vaccine screening platform to develop a vaccine against SARS-CoV-2 for Singapore. Arcturus’ STARR...
BioCentury | Jan 29, 2020
Company News

Decibel narrows discovery focus to inner ear regeneration, taps Reid as CEO

...remain a strategic adviser to Decibel (see "Branching Out" ). Holtzman succeeded Third Rock's Kevin Starr...
BioCentury | Aug 7, 2019
Financial News

Glycomine looks toward clinic with Novo-led $33M round

...joined Glycomine's board, as did BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and Raptor Pharmaceutical Corp. co-founder Chris Starr...
BioCentury | Jun 2, 2017
Product Development

Ears wide open

...important because they start to change how ENTs work and how they prescribe treatments." Kevin Starr...
...because they start to change how ENTs work and how they prescribe treatments,” said Kevin Starr...
...or pathways it is working on. Decibel is not developing therapies that deliver NFT3, but Starr...
BioCentury | Jul 14, 2016
Company News

Decibel hires Holtzman as CEO

...Millennium Pharmaceuticals Inc. , which Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) acquired. Third Rock Ventures' Kevin Starr...
...remain its chairman. Third Rock led Decibel's $52 million series A round in October 2015. Starr...
BioCentury | Jan 11, 2016
Emerging Company Profile

Synaptic sound

...or other injuries mean your hair cells are gone," said Chairman and interim CEO Kevin Starr...
...we can generate a therapy that makes the synapse healthier, we can help improve hearing." Starr...
...children often go on to get cochlear implants and grow up to be deaf," said Starr...
BioCentury | Oct 19, 2015
Finance

Sound check

...and hearing disorders were not going to be a black box," said the firm's Kevin Starr...
...product in the clinic in three years. The series A will last that long, said Starr...
...play Otonomy Inc. (NASDAQ:OTIC). Compared with those companies, which house one or two key assets, Starr...
BioCentury | Oct 16, 2015
Financial News

Decibel raises $52M series A

...loss. Decibel is not disclosing the precise mechanisms of its preclinical programs. Third Rock's Kevin Starr...
BioCentury | Jun 24, 2015
Company News

Agios makes boardroom changes

...York, N.Y.). Ho was a partner at Goldman Sachs Group. Third Rock Ventures partner Kevin Starr...
Items per page:
1 - 10 of 54